
| 1) dies (0.18% of the participants) included patients with a PBT diagnosis, potentially |
| 2) ts were compared with the TT genotype and patients with a genotype containing a G al |
| 3) 12 to phenylalanine has been described in patients with a hyperkinetic movement diso |
| 4) ing includes a residue that is mutated in patients with a hyperkinetic movement diso |
| 5) iction of long-term allograft survival in patients with a kidney transplant. |
| 6) Of 248 patients with a median age of 69 years ( |
| 7) of oral health-related quality of life in patients with a mental health disorder, it |
| 8) and appraise oral health interventions in patients with a mental health disorder. |
| 9) ibodies were both significantly higher in patients with a poor clinical outcome than |
| 10) linical studies describing critically ill patients with a sample size of greater tha |
| 11) nd apraxia in healthy subjects and stroke patients with a scoping review using PRISM |
| 12) looking at treatment with osimertinib in patients with a specific type of non-small |
| 13) apering seems to be effective and safe in patients with a stable low disease activit |
| 14) A total of 357 patients with a thyroid gland in loco typi |
| 15) Patients with severe COVID-19 pneumonia ma |
| 16) Patients with severe HAV and liver dysfunc |
| 17) Patients with severe coronavirus disease i |
| 18) Patients with severe visual vertigo improv |
| 19) yed an important role in the treatment of patients with severe COVID-19 disease. |
| 20) ffects of PE and HP on cytokine storms in patients with severe COVID-19 through a sy |
| 21) activity and mitochondrial dysfunction in patients with severe COVID-19. |
| 22) Some patients with severe Covid-19 experience a |
| 23) Thirty-seven (53.6%) patients with severe HAV were hospitalized |
| 24) ngaging in rehabilitation, nearly half of patients with severe TBI requiring hospita |
| 25) h red blood cell transfusion in admitted patients with severe acute gastrointestina |
| 26) mean antibiotic prescribing rate between patients with severe or critical illness ( |
| 27) ients compared with levels in plasma from patients with severe or mild COVID-19, wit |
| 28) ESPB was performed in patients with severe pain and in all cases |
| 29) Patients with COVID-19 (n = 172) had mar |
| 30) Patients with COVID-19 displayed markers o |
| 31) ulating neutrophil populations, comparing patients with COVID-19 ARDS and non-COVID- |
| 32) association study in 2,244 critically ill patients with COVID-19 from 208 UK intensi |
| 33) eta-analyses that consist of up to 49,562 patients with COVID-19 from 46 studies acr |
add keyword